retatrutide safety retatrutide clinical trial Investigating the “efficacy and of retatrutide”, Eli Lilly saw " clinically meaningful weight loss” in a phase three ㅤ Go to the C+D website through the link 🔗in the bio Phase 2 Trial of Retatrutide

When to Talk to a Doctor See a doctor if shedding lasts several months or worsens

Retatrutide May Be Preferred For Patients with severe obesity requiring maximum weight loss MASH / fatty liver disease where liver fat reduction is a treatment goal Cases where energy expenditure enhancement could provide additional benefit Patients who have plateaued on dual-agonist therapy Tirzepatide May Be Preferred For Type 2 diabetes with weight management (approved indication) Patients who prioritize an established safety profile Cardiovascular risk populations (pending SURPASS-CVOT data) Settings requiring an FDA-approved, commercially available option The Bottom Line Comparing retatrutide and tirzepatide today is comparing a promising research compound against a proven pharmaceutical

Patients with pre-existing gastrointestinal conditions, those who have undergone bariatric surgery (who typically require specific bariatric-formulation supplements), or individuals following restrictive diets (vegetarian, vegan) may enter GLP-1 treatment with suboptimal nutrient status

& Fava, J

case-by-case assessment) Severe uncontrolled depression, anxiety, or eating disorders (risk of worsening) Pregnancy or intent to become pregnant (GLP-1 safety in pregnancy not established

Similarly, abdominal exercises after an abdominal injection could theoretically increase local absorption speed